We explored the impact of cholecalciferol, also known as vitamin D3, on individuals with calcium nephrolithiasis and a deficiency in vitamin D. The purpose of our investigation was to determine whether this supplementation might lead to an increased risk of developing kidney stones.
In the study, thirty-three participants, averaging 56 years and deficient in vitamin D, were evaluated before and after receiving cholecalciferol supplements. Initially, we examined both their calcium excretion and urine supersaturation levels, which help indicate the risk of stone formation.
Following the supplementation, we observed several significant changes. Notably, the serum levels of vitamin D increased, and more participants became hypercalciuric, meaning they were excreting higher levels of calcium in their urine. This was concerning as increased urine supersaturation with calcium could elevate the risk of kidney stones.
Despite the rise in vitamin D levels, we didn’t see any major changes in overall calcium levels in the blood, suggesting that the body was managing these variations. However, for those undergoing this treatment, there remains a cautionary note about the potential for increased stone formation due to higher calcium excretion.